GEN1 is an inclusion criterion in 2 clinical trials for prostate adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain GEN1 status and prostate adenocarcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].

GEN1 is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains GEN1 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [4].

GEN1 is an inclusion criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains GEN1 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

GEN1 is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains GEN1 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

GEN1 is an inclusion criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains GEN1 status and prostate carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].